What Happened After the Signing Ceremony

Trump's April 18 executive order and the FDA's initial voucher announcements have been followed by concrete action.

The FDA announced a full package of measures — priority vouchers for companies studying psilocybin for depression and methylone for PTSD, plus a green light for an early-stage clinical trial of noribogaine hydrochloride, a derivative of ibogaine.

This is the first time any compound like noribogaine has been authorized for human trial in the United States. The target: alcohol use disorder. A drug family that's been Schedule I for decades just got its first American human trial cleared.

The Timeline Is Real

FDA Commissioner Marty Makary told CNBC directly: decisions on some of these therapies could come as soon as this summer or fall. That's an extraordinarily compressed timeline for drug approvals.

He was also blunt about what approval would look like: "These are not the medications you get a prescription for and pick up at a pharmacy." Approvals, if they come, will carry conditions.

HHS Secretary Robert F. Kennedy Jr. said the FDA will prioritize therapies with Breakthrough Therapy designation, where early evidence already shows meaningful improvement.

$50 Million on the Table

According to NPR, Trump directed $50 million in federal funds toward making these therapies more accessible. That money is tied to the executive order signed in the Oval Office, where the cast of characters included RFK Jr., CMS Administrator Dr. Mehmet Oz, former Navy SEAL Marcus Luttrell, and podcast host Joe Rogan.

Rogan told NPR he had texted Trump about ibogaine and the president responded: "Sounds great. Do you want FDA approval? Let's do it."

Luttrell — whose story became the film Lone Survivor — told Trump directly: "You're going to save a lot of lives through it. It absolutely changed my life for the better."

The Federal Trials Are Happening Now

Most coverage frames this as a culture war curiosity — Trump the anti-drug hardliner suddenly supporting psychedelics. The actual story is elsewhere.

The Department of Veterans Affairs is now participating in at least five active clinical trials of psychedelic drugs — in New York, California, and Oregon — according to NPR. The federal government is running experiments on veterans right now.

Also worth noting: the FDA's disclaimer buried in the announcement. According to CNBC, the agency explicitly stated that "allowing these studies to proceed does not mean the drugs are approved or proven safe and effective" and that data will be closely monitored. The safety guardrails remain in place.

The Safety Question

CNBC noted that psychedelic therapy brings "new scrutiny about safety and effectiveness" as trials move forward.

Psilocybin, MDMA-like compounds, and ibogaine derivatives are not aspirin. Ibogaine in particular has documented cardiac risks. The fact that noribogaine — a derivative designed to reduce those risks — just got its first U.S. human trial cleared reflects that the parent compound has a dangerous track record.

Makary's conditional approval language is important. The FDA isn't throwing open the pharmacy window. But the speed of this process — vouchers issued, trials cleared, approvals possible within months — is fast by any historical standard for Schedule I-adjacent substances.

The VA's involvement in five active trials means real veterans are in these studies right now. If something goes wrong, it won't be a theoretical debate.

The Stakes Going Forward

For a veteran with PTSD, or someone with treatment-resistant depression who has exhausted standard medications, this pipeline represents the most significant development in mental health treatment in a generation.

For taxpayers, $50 million just got committed to this effort, and the compressed approval timeline means less time to catch problems before they hit patients at scale.

The science on psychedelic-assisted therapy is real and growing. The political support is now real too. The next few months will show whether the safety infrastructure can keep pace with the speed of political momentum.